|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
The FLT3 receptor tyrosine kinase plays an integral role in hematopoiesis, and one third of AML diagnoses exhibit gain-of-function mutations in FLT3, with the juxtamembrane domain internal tandem duplication (ITD) and the kinase domain D835Y variants observed most frequently.
|
30541869 |
2019 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Retroviral expression of FLT3-N676K in myeloid 32D cells induced AML in syngeneic C3H/HeJ mice (n = 11/13, median latency 58 days), with a transforming activity similar to FLT3-internal tandem duplication (ITD) (n = 8/8), FLT3-TKD D835Y (n = 8/9), and FLT3-ITD-N676K (n = 9/9) mutations.
|
26891877 |
2016 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
T |
0.740 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
T |
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.
|
24046014 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.
|
24046014 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
|
23714533 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
|
23714533 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
T |
0.740 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
T |
0.740 |
CausalMutation
|
CLINVAR |
The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
|
23714533 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
T |
0.740 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.
|
22504183 |
2012 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
T |
0.740 |
CausalMutation
|
CLINVAR |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
|
22368270 |
2012 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
G |
0.740 |
CausalMutation
|
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |
|
rs121913488
|
|
Leukemia, Myelocytic, Acute
|
A |
0.740 |
CausalMutation
|
CLINVAR |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
|
22368270 |
2012 |